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hazard models were then constructed for time to stroke and atrial fibrillation 
(AF) diagnoses through 2010. Hazard ratios (HR) were computed for each value of 
the predictor variable. RESULTS: Among patients with one risk factor, age 75+ 
was most strongly associated with the occurrence of both stroke and AF (HR 6.87 
and 9.16, respectively), followed by HF (HR 4.48 and 4.70). Hypertension (HR 2.06 
and 2.64) and diabetes (HR 2.03 and 1.82), along with age, were the risk factors 
with the highest prevalence. For patients age 75+, the additional presence of 
HTN or diabetes conferred nearly additive risk for stroke or AF (HR 9.64 and 14.83 
with HTN; 9.93 and 11.64 with diabetes). In contrast, the combination of age 75+ 
and HF on the risk of AF was supra-additive (HR 28.63). CONCLUSIONS: 
Previously established, common risk factors were found to be strongly associated 
with the subsequent occurrence of stroke and AF in a claims database. 
Additionally, the proposed methodology, combined with the large sample size of 
a claims database, provided valuable and easily interpretable insights on the 
levels of interactions among risk factors. Similar methodology may prove useful 
for establishing important risk combinations and interactions in the treatment 
and prevention of other conditions.  
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OBJECTIVES: To evaluate the potential economic implications of alternative 
treatment strategies for acute bacterial skin and skin structure infections 
(ABSSSIs) by capturing the impact of the initial empiric antibiotic selection, 
switches to 2nd line antibiotics, course length, route of administration and 
location of care. METHODS: The treatment pathway of each patient is simulated 
through various locations (emergency department (ED), inpatient, and 
outpatient). Patients responding at 72 hours may transfer to the outpatient 
setting to complete the course, switch antibiotic at discharge or receive 2nd line 
treatment due to lack of response or relapse. Analysis of US inpatient claims 
(Premier Hospital Database) provided length of stay information. Results from 
three scenarios are presented - each cohort was assigned to 1st line vancomycin 
(VAN). At discharge, one cohort completed the VAN course, one switched to oral 
linezolid (LIN) and the other to daptomycin (DAP). Costs (2012 USD from the 
Medicare perspective) and time in each location are accrued throughout the 
entire treatment course. RESULTS: Compared to VAN (10.1), hospital plus 
outpatient days were greater with LIN (13.4) and DAP (10.8), but total costs were 
reduced by $2,465 and $252 with LIN and DAP respectively, suggesting avoiding 
repeated outpatient infusion center visits lowers costs. Outpatient care 
comprises 32% (LIN) to 50% (VAN) of total costs and will remain important to 
consider as treatment pathways move further towards the outpatient setting. 
CONCLUSIONS: The choice of antibiotic and location of care have a substantial 
impact on resource use and costs. The economic implications of new treatment 
options currently in development such as long-acting lipoglycopeptide IV 
antibiotics (oritavancin and dalbavancin), which avoid repeated infusions and 
are anticipated to allow providers to shift more care to the ambulatory setting, 
can be assessed using the modeling framework presented here.  
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OBJECTIVES: To compared model fit and impact on key treatment effect 
estimates from incorporating the assumption of drug class effects in MTCs. 
METHODS: Two MTC data sets on early and advanced Parkinson’s disease (PD) 
comprising of several pharmacotherapies belonging to one of the three drug 
classes: dopamine receptor agonists (DOAs), monoamine-oxidase B inhibitors 
(MOAB-I), and adenosine A2 antagonists (A2A). We used three models: 1) a 
conventional random-effects MTC assuming all drugs were independent (model 
1); 2) an MTC assuming all drug belonging to the same class exhibited equal 
effects (model 2); and 3) an MTC assuming some overall drug class effect for each 
drug class, but allowing for each drug to differ from their class’ overall effect 
(model 3). We analysed the effect of the included interventions (and drug 
classes) on improvement on the Unified Parkinson’s Disease Rating Scale 
(UPDRS) part II and III. We compared model fits (DIC) and the impact on 
treatment effects and 95% credible intervals from using these three models. 
RESULTS: For the early PD data set, the model 3 yielded the smallest DIC. 
Treatment effects from all models were similar, but 95% credible intervals were 
generally narrower with model 3 and generally the widest with model 1. For the 
advanced PD data set, model 2 yielded a slightly smaller DIC than model 3, and 
both smaller DIC than model 1. However, all treatment effects and 95% credible 
intervals were highly similar. CONCLUSIONS: Incorporating the drug class effect 
assumption in MTCs may provider better model fits, and thus, more reliable 
estimates of comparative efficacy and safety.  
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OBJECTIVES: To quantify preferences for allocating hypothetical time savings in 
cystic fibrosis (CF) inhaled antibiotic treatment among health care and non-
health care activities. METHODS: Adult patients with a self-reported physician 
diagnosis of CF and parents of juvenile CF patients in the United States who have 
Pseudomonas aeruginosa in their culture at least twice a year completed a web-
enabled, discrete-choice experiment survey. Respondents evaluated treatment-
choice and routine-choice alternatives followed by stated adherence for 
themselves and other people. Questions required evaluating pairs of 
hypothetical inhalation devices and routine profiles defined by inhalation device 
features, side effects, time spent on inhaled antibiotic treatment, time spent on 
hypertonic saline, time spent on other CF-care activities, and lung function 
measured as forced expiratory volume in one second (FEV1). Respondents also 
answered a question indicating how they would allocate 80 hypothetical minutes 
of time savings per day among CF-care and non-CF-care activities (work, sleep, 
family activities, and social activities). Using a conceptual framework describing 
optimal time allocations within a health production function, random-
parameters logit models were used to quantify trade-off preferences among 
efficacy, treatment-time adherence, and competing time demands. RESULTS: 
The final sample included 174 adult patients and 130 parents. On average, adult 
patients would spend 9% of the time saved on additional CF-care activities and 
the remaining time would be almost evenly split between work, social activities, 
and sleep. Juvenile patients would spend 11% of the time saved on additional CF-
care activities and about 2.5 times more minutes in social activities than in work 
and 2 times more minutes in social activities than in sleep. CONCLUSIONS: 
Some of the time saved on taking inhaled antibiotics would be reallocated to 
activities with treatment benefits such as exercise and taking hypertonic saline 
as well as activities such as sleep that may improve health outcomes.  
 
PRM77  
EXAMINING THE IMPACT OF EQ-5D AND LONG-STANDING HEALTH 
CONDITIONS ON SUBJECTIVE WELL-BEING  
Wu M1, Brazier J2 
1University of Sheffield, Sheffield, UK, 2University of Sheffield, Sheffield, South Yorkshire, UK  
OBJECTIVES: Generic preference-based measures like EQ-5D and SF-6D have 
been criticised for being narrowly focused on sub-set of health dimensions. One 
potential solution to this problem is to use the increasingly promoted subjective 
well-being approach, which considers the overall impact on a person’s well-
being and is based on experiences rather than hypothetical preferences. The aim 
of this study is to explore whether EQ-5D is adequate in reflecting the impact of 
long-standing health conditions on life satisfaction. METHODS: Using data from 
a UK general population cohort health (N = 13,591) collected between 2010 and 
2012 on EQ-5D, long-standing health conditions (self-reported), and life 
satisafaction using a response scale from 1 (completely dissatisfied) to 6 
(completely satisfied), this study employs ordered and generalised logit 
regression models. The impact of EQ-5D and long-standing health conditions on 
life satisfaction is assessed by examining the coefficients on dummy variables. 
RESULTS: The EQ-5D alone has coefficients that suggest anxiety/depression has 
the largest impact on life satisfaction (odds ratios ranging from 0.65 to 0.26). Self-
care has less impact (0.78) and pain/discomfort has the least (0.91). The long-
standing health conditions alone have coefficients that suggest insomnia has the 
largest impact on life satisfaction (0.71). The EQ-5D and long-standing health 
conditions have coefficients that suggest insomnia have a strong impact on life 
satisfaction (0.86) in the ordered logit model. Diabetes has a stronger impact on 
life satisfaction (0.72) in the generalised logit model. The largest difference in 
coefficients between the models is observed for severe anxiety/depression (odd 
ratio dropped significantly from 0.60 to 0.26). CONCLUSIONS: This study provides 
evidence of statistically significant differences between the models, and the 
comparison of the coefficients suggests inclusion of the bolt-on extra 
dimensions for EQ-5D could affect life satisfaction. Therefore, diabetes and 
insomnia could be newly discovered bolt-on dimensions for EQ-5D.  
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OBJECTIVES: To compare the effect of using PTC or MTC on the results of cost-
effectiveness analysis of pharmacotherapies for chronic obstructive pulmonary 
disease (COPD). METHODS: A discrete-time Markov model was developed to 
reflect the cost and effectiveness of five COPD commonly used interventions 
including inhaled corticosteroids (ICS), long-acting beta agonists (LABA), 
ICS+LABA, long-acting muscarinic agents (LAMA), and no treatment (placebo). 
We pooled rate ratios (RR) of preventing COPD exacerbations using both Bayesian 
PTC and Bayesian MTC methods. We compared the impact of PTC versus MTC on 
the outcomes of the expected value of information (EVI) analysis. RESULTS: The 
expected value of perfect information (EVPI) values at willingness-to-pay of 
$50,000/QALY for all permutations of comparisons were calculated and 
compared between PTC and MTC analyses. The EVPI when all 5 treatments are 
compared is $1,281.1 for PTC and $557.3 for MTC analyses. When the future trial 
is planned to have only two intervention arms, among all ten possible 
permutations, the RCT that compares Placebo versus ICS+LABA had the highest 
EVPI when evidence was synthesized using MTC; on the other hand the RCT that 
compares LABA versus ICS+LABA had the highest EVPI using PTC analysis. 
Similarly, for RCTs with three and four arms, the strategy with highest EVPI 
changed across MTC and PTC analyses. CONCLUSIONS: The evidence generated 
using the entire network of comparisons resulted in substantial changes in the 
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estimated opportunity loss due to uncertainty, compared with the situation in 
which the evidence was synthesized using traditional pairwise meta-analysis. 
The nominal value of EVPIs varied considerably between the two schemes, with 
potential to have an impact on the justifiability and the optimal sample size of 
the future RCT.  
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OBJECTIVES: In cost-effectiveness literature, several Markov models with 
different health states and assumptions are used to estimate cost-effectiveness 
for treatment of advanced breast cancer (ABC). This study aims to (1) derive the 
relationships among the Markov models for ABC, and (2) examine the impact of 
using different Markov models on cost-effectiveness results for treatment of 
HER2-positive advanced breast cancer. METHODS: There are four Markov models 
for ABC: (i) model 1 includes 4 health states (stable, response, progression, and 
dead) with a possibility of death can occur in all health states; (ii) model 2 also 
consists of 4 health states but the chance of dying can only occur at disease-
progression state; (iii) model 3 is the most common model and has 3 health 
states (stable, progression, and dead) with a possibility of death can occur in all 
health states; and (iv) model 4 also has 3 health states but the chance of death 
can only occur at disease-progression state. Relationships of transition 
probabilities among the Markov models were derived. A simulation method was 
used to generate 10,000 samples with transition probabilities, estimated costs 
and utilities for each health state based on a previously published cost-
effectiveness study of lapatinib in treatment of HER2-positive advanced breast 
cancer. RESULTS: Markov models 2 and 4 yielded similar and lowest incremental 
cost-effectiveness ratios (ICER), while the commonly used Markov model (model 
3) produced the highest ICER. All four Markov models produced ICERs > $150,000 
per additional quality-adjusted life year gained for the combination therapy with 
lapatinib as compared to monotherapy with capecitabine. CONCLUSIONS:  
This study suggests that modeling advanced breast cancer with different health-
state Markov models may produce different cost-effectiveness results. 
Combination therapy with lapatinib in treatment of HER2-positive advanced 
breast cancer is not a cost-effective treatment strategy regardless which Markov 
models used.  
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OBJECTIVES: Economic modeling and health care cost analyses are used to 
inform policy-makers in health care decision-making such as cost-of-illness 
assessments, treatment evaluation studies, and more commonly to predict 
health care costs for specific patient populations. However, due to stochastic 
error distribution assumptions and the challenges they create for econometric 
modeling, various types of models have been identified to address specific 
distributional characteristics. The objective of study is to examine cost 
distributions for treated diabetes patients and compare untransformed ordinary 
least squares (OLS) regression with log transformed OLS and generalized linear 
model (GLM) methods. METHODS: A simulated distribution was created 
mirroring a representative claims dataset for type 2 diabetes costs. Using 
simulated cost distributions with known error term ensures that model selection 
could be assessed with certainty of the error specification for the distribution. 
Two simulated cost distributions were generated: one with homoskedastic errors 
and the other with heteroskedastic errors. Both distributions were used to 
explore model performance under varying conditions. Several tests for model fit, 
specification, and predictive ability were selected from the existing literature to 
assess model selection and determine best model fit. Simulation and all analyses 
were done using STATA 11. RESULTS: Results from the model specification tests 
indicate that for both cost error distributions, OLS regression on untransformed 
Y is the best-fitting model of the three tested. Although superior in model fit, 
prediction criteria indicate that OLS is relatively poor in prediction along the 
entire range of costs. CONCLUSIONS: OLS on untransformed Y cost model is 
selected as the best model choice under the conditions of the given distributions. 
The inability for all three models to predict within the full range of costs 
demonstrates weakness in characterizing the upper tail of the distribution. If 
prediction is the primary concern, a two-part model may be more appropriate.  
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OBJECTIVES: When modeling long-term costs and health effects using Markov 
models, choosing the time of transition to another state (progression of the 
disease) seems to influence the final results. Various approaches can be adopted, 
i.e. transitions at the beginning, at the end or in the middle of the cycle. Our aim 
is to measure influence of cycle length and progression rates on differences 
between final results obtained using those methods and to establish whether 
there is an optimal cycle length for which half cycle correction (HCC) should 
always be applied. METHODS: A simple, hypothetical, two-state Markov model 
was built. The time horizon was set to be lifetime, an outcome discount rate was 
0% or 5% and costs/utilities were held constant in time. Assuming different 
progression rates (0.05–0.90 annually), three methods were compared: transitions 
at the beginning of the cycle (‘beginning’), at the end of the cycle (‘end’), in the 
middle of the cycle (HCC). For each parameter the threshold values were 
determined, i.e. the maximal cycle length for which the difference between half-
cycle correction and ’beginning’/‘end’ methods were not greater than 5%. We 
assumed that cycles longer than the estimated threshold will imply the 
application of HCC. RESULTS: For 5% discount rate the threshold cycle length 
was 1 year for annual progression of 0.05 and it became shorter for lower 
progression rates (2 weeks for 0.90 progression rate). Assuming no discounting, 
the threshold was 2 years for annual progression of 0.05 and 2 weeks for 
progression of 0.90. CONCLUSIONS: Choice of the time of transitions in the 
model may have a significant impact on results. For cycles shorter than 2 weeks 
HCC does not seem to be necessary, however it should always be applied for 
cycles longer than 1 year. For cycles between 2 weeks and 1 year a general 
recommendation cannot be made.  
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OBJECTIVES: Health Technology Assessment (HTA) has during the last decades 
become an increasingly important tool for the introduction of new health care 
interventions. The aim of HTA is to assist payers in making informed decisions 
about allocating resources in the health care system. The use of decision-
analytic modelling (DAM) to aid HTA represents an explicit approach to 
synthesizing available evidence and provides support in reimbursement 
decisions under conditions of uncertainties. Probabilistic sensitivity analysis 
(PSA) is generally viewed as the most appropriate method of handling parameter 
uncertainty as it provides assessment of the joint effect of uncertainty over all 
ingoing parameters. It also facilitates value-of-information analysis that can 
quantify the implications of decision uncertainty explicitly and investigate the 
value of further studies. The objective of this study is to explore the value given 
to probabilistic decision modelling in the context of health technology 
assessment in England and Scandinavia. METHODS: A systematic search was 
undertaken to identify the current guidelines of the HTA bodies in England and 
Scandinavia (Sweden, Norway, and Denmark), specifically extracting all 
information relating to approaches of assessing uncertainties in DAM and the 
request for probabilistic analysis (e.g. incremental net benefit (INB) analysis or 
expected-value-of-perfect-information methods (EVP(P)I). RESULTS: All the 
reviewed HTA agencies and reimbursement authorities require deterministic 
sensitivity analysis for primary assumptions whereas only two agencies 
specifically require an addition of a PSA. The guidelines from the National 
Institute for health and Clinical Excellence (NICE) in the UK express strong 
support of conducting PSA, but have no requirements for the inclusion of EVP(P)I. 
The Norwegian Medicines Agency (NoMA) guidelines mentions both INB analysis 
and EVP(P)I. The remaining countries have no specific requirements regarding 
probabilistic modelling at all. CONCLUSIONS: The recent inclusion 
recommendations of INB and EVP(P)I in Norway indicate a growing recognition of 
the value of probabilistic analysis.  
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OBJECTIVES: Unlike modeling chronic diseases such as diabetes, ILS for oncology 
drugs health technology assessment (HTA) is rare because of short treatment 
duration, simple disease states and treatment pathways. With new drugs filling 
the space of mild symptomatic or asymptomatic cancer patients, researchers 
start to embrace the method of ILS because it can better predict survival and 
other events by individual patient tracking, and simulate trials and real world 
clinical practice. It has not been widely endorsed by HTA payers due to lack of 
simplicity and transparency. The objective of this study is to review and catalog 
different modeling methods used in NICE submissions for advanced/metastatic 
cancer treatments, understand when NICE is looking for ILS. METHODS: A 
targeted search of NICE website found 68 NICE rulings happened between 2000 
and 2012 for oncology drugs. We extracted information on the model used, the 
application setting, the method and data used to model cancer evolution. 
RESULTS: Survival trees and Markov cohort models were most commonly 
employed. Simulation methods evolved from simple decision trees to more 
complex Markov models over the last decade. ILS model was submitted to NICE 
for decision making by manufacturers. NICE stated that it would accept the 
discrete event simulation model, a type of ILS, if manufacturer made a well 
justified case. When multiple treatments and/or patient heterogeneity exist, and 
such complexity influences cost and health outcomes, NICE encouraged the 
method of ILS. For example, ILS was suggested in modeling the first line 
maintenance of Rituximab in treating the stage III-IV follicular lymphoma and 
first line treatment of Imatinib in treating metastatic gastro-intestinal stromal 
tumors. CONCLUSIONS: ILS emerges as a modeling method for cancer treatment 
because it provides a framework for natural representation of disease and 
resource use. Although it is a more sophisticated approach, some HTAs like NICE 
start to support this method.  
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